-+ 0.00%
-+ 0.00%
-+ 0.00%

Novartis says Phase III RemIND trial shows Rhapsido hits endpoints in chronic inducible urticaria

PUBT·06/12/2026 09:36:19
Listen to the news
Novartis says Phase III RemIND trial shows Rhapsido hits endpoints in chronic inducible urticaria
  • Novartis presented Phase III RemIND data at the EAACI congress, showing Rhapsido improved symptom control across common chronic inducible urticaria subtypes.
  • Results supported sustained relief in patients not adequately controlled on standard antihistamines, with responses emerging early in parts of the study.
  • Safety profile remained favorable, with no liver safety signal reported in the trial readout.
  • Regulatory review is underway in the US for the symptomatic dermographism subtype, positioning Rhapsido as a potential first targeted option in CIndU.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novartis AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606120536OMX_____CNEWS_EN_GNW1001187340_en) on June 12, 2026, and is solely responsible for the information contained therein.